Negotiamini Media
Truth is Powerful

Invitae adds Medneon’s risk assessment tools to its education and clinical support offerings


SAN FRANCISCO, Feb. 24, 2021 /PRNewswire/ — Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the addition of tools from Medneon, a digital health AI company, to its robust clinical workflow and patient education tools. The additional capabilities further support clinicians and patients with cancer by making it easier to determine who should get testing and how to use genetic information to individualize treatment. Invitae’s (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. (PRNewsFoto/Invitae Corporation) “While utility of genetic information in cancer care is well established, it remains challenging for clinicians to navigate varying guidelines and research findings that inform them about which patient, which test and what results mean for patient care,” said Robert Nussbaum, M.D., chief medical officer at Invitae. “The addition of Medneon’s risk assessment tool, which was developed by experts in the field, makes it easier for clinicians to make sure testing is considered and findings are acted upon for all patients who could benefit from genetic-informed care. The frequent updating of Medneon’s recommendations based on the most current recommendations and newest research findings means that providers […]

Click here to view original web page at


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More